These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6354827)

  • 1. Treatment of Crohn's disease with peroral 5-aminosalicylic acid.
    Rasmussen SN; Binder V; Maier K; Bondesen S; Fischer C; Klotz U; Hansen SH; Hvidberg EF
    Gastroenterology; 1983 Dec; 85(6):1350-3. PubMed ID: 6354827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.
    Saverymuttu SH; Gupta S; Keshavarzian A; Donovan B; Hodgson HJ
    Digestion; 1986; 33(2):89-91. PubMed ID: 3512352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.
    Griffiths A; Koletzko S; Sylvester F; Marcon M; Sherman P
    J Pediatr Gastroenterol Nutr; 1993 Aug; 17(2):186-92. PubMed ID: 8229546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid].
    Maier K; Frühmorgen P; Bode JC; Heller T; von Gaisberg U; Klotz U
    Dtsch Med Wochenschr; 1985 Mar; 110(10):363-8. PubMed ID: 2857633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
    Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
    Mahida YR; Jewell DP
    Digestion; 1990; 45(2):88-92. PubMed ID: 2190851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.
    Rasmussen SN; Lauritsen K; Tage-Jensen U; Nielsen OH; Bytzer P; Jacobsen O; Ladefoged K; Vilien M; Binder V; Rask-Madsen J
    Scand J Gastroenterol; 1987 Sep; 22(7):877-83. PubMed ID: 3313678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
    Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
    Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
    Bayerdörffer E; Bock H
    Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.